Mindfulness-based Relapse Prevention for Substance Use Disorders: A Systematic Review and Meta-analysis

Journal of Addiction Medicine

Volumn 11, Issue 5, 2017, Pages 386-396

  Grant, Sean ^a   Colaiaco, Benjamin ^a   Motala, Aneesa ^a   Shanman, Roberta ^a   Booth, Marika ^a   Sorbero, Melony ^a   Hempel, Susanne ^a  

^a RAND CORPORATION   (United States)

Author keywords

meta analysis; mindfulness; substance use disorder; systematic review

Indexed keywords

ANXIETY DISORDER; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG DEPENDENCE; HUMAN; META ANALYSIS; MINDFULNESS; PATIENT DROPOUT; PATIENT SAFETY; PRIORITY JOURNAL; RELAPSE; REVIEW; SUBSTANCE USE; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME; OUTCOME ASSESSMENT; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

HUMANS; MINDFULNESS; OUTCOME ASSESSMENT (HEALTH CARE); SECONDARY PREVENTION; SUBSTANCE-RELATED DISORDERS;

EID: 85029747288     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000338     Document Type: Review

References (84)

1. Alonso-Coello P, Schunemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction. BMJ 2016;353: i2016.
2. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-406.
3. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
4. Black DS. Mindfulness-based interventions: an antidote to suffering in the context of substance use, misuse, and addiction. Subst Use Misuse 2014;49:487-491.
5. Boutron I, Dutton S, Ravaud P, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-2064.
6. Bowen S, Chawla N, Collins S, et al. Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abuse 2009;30: 205-305.
7. Bowen S, Chawla N, Marlatt GA. Mindfulness-based Relapse Prevention for Addictive Behaviors: A Clinician's Guide. New York, NY: Guilford Press; 2010
8. Bowen S, Chawla N, Marlatt GA. Mindfulness-based Relapse Prevention for Addictive Behaviors: A Clinician's Guide. New York, NY: Guilford Press; 2011.
9. Bowen S, Chawla N, Witkiewitz K. Mindfulness-based relapse prevention for addictive behaviors. In: Baer R, editor. Mindfulness-based Treatment Approaches: A Clinician's Guide. 2nd ed., San Diego, CA: Elsevier Academic Press; 2014.
10. Bowen S, Witkiewitz K, Clifasefi SL, et al. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry 2014;71:547-556.
11. Brandon TH, Vidrine JI, Litvin EB. Relapse and relapse prevention. Annu Rev Clin Psychol 2007;3:257-284.
12. Brewer DD, Catalano RF, Haggerty K, et al. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998;93:73-92.
13. Brewer JA, Sinha R, Chen JA, et al. Mindfulness training and stress reactivity in substance abuse: results from a randomized, controlled stage I pilot study. Subst Abuse 2009;30:306-317.
14. Brewer JA, Elwafi HM, Davis JH. Craving to quit: psychological models and neurobiological mechanisms of mindfulness training as treatment for addictions. Psychol Addict Behav 2013;27:366-379.
15. Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol 2003;84:822.
16. Cargiulo T Understanding the health impact of alcohol dependence. Am J Health Syst Pharm 2007;64:S5-S11.
17. Carroll KM. Relapse prevention as a psychosocial treatment: a review of controlled clinical trials. Exp Clin Psychopharmacol 1996;4:46-54.
18. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ 2013;346:e7586.
19. Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Commun Stat Simul Comput 2010;39:860-864.
20. Chiesa A, Serretti A. Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. J Altern Complement Med 2009;15:593-600.
21. Chiesa A, Serretti A. Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse 2014;49:492-512.
22. Connors GJ, Maisto SA, Donovan DM. Conceptualizations of relapse: a summary of psychological and psychobiological models. Addiction 1996;91(Suppl 1 to Issue 12):5-14.
23. Craig AD. How do you feel: now? the anterior insula and human awareness. Nat Rev Neurosci 2009;10:59-70.
24. de Lisle SM, Dowling NA, Allen JS. Mindfulness and problem gambling: a review of the literature. J Gambling Studies 2011;28:719-739.
25. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
26. Duval SJ, Tweedie RL. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463.
27. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
28. Garland EL, Froeliger B. Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface. Front Psychiatry 2013;4 (173).
29. Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. BMJ 2016;354:i3507.
30. Glasner S, Mooney LJ, Ang A, et al. Mindfulness-based relapse prevention for stimulant dependent adults: a pilot randomized clinical trial. Mindfulness 2017;8:126-135.
31. Gottfredson DC, Cook TD, Gardner FE, et al. Standards of evidence for efficacy, effectiveness, and scale-up research in prevention science: next generation. Prev Sci 2015;16:893-926.
32. Grant S, Montgomery P, Hopewell S, et al. Letter to the Editor: new guidelines are needed to improve the reporting of trials in addiction sciences. Addiction 2013;108:1687-1688.
33. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015;72:757-766.
34. Grant S, Hempel S, Colaiaco B, et al. Mindfulness-based Relapse Prevention for Substance Use Disorders: A Systematic Review; RR-1031. RAND Corporation, Santa Monica; 2015.
35. Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions: III. JAMA Psychiatry 2016;73:39-47.
36. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence: imprecision. J Clin Epidemiol 2011;64: 1283-1293.
37. Hartung J. An alternative method for meta-analysis. Biom J 1999;41: 901-916.
38. Hartung J, Knapp G. A refined method for the meta analysis of controlled clinical trials with binary outcome. Stat Med 2001;20: 3875-3889.
39. Hasenkamp W, Barsalou LW. Effects of meditation experience on functional connectivity of distributed brain networks. Front Hum Neurosci 2012;6:38.
40. Hasenkamp W, Wilson-Mendenhall CD, Duncan E, et al. Mind wandering and attention during focused meditation: a fine-grained temporal analysis of fluctuating cognitive states. Neuroimage 2012;59:750-760.
41. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-560.
42. Higgins J, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172:137-159.
43. Higgins J, Altman D, Gøtzsche P, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
44. Hodgins DC, el-Guebaly N, Armstrong S. Prospective and retrospective reports of mood states before relapse to substance use. J Consult Clin Psychol 1995;63:400.
45. Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 2010;78:169.
46. Imani S, Vahid MKA, Gharraee B, et al. Effectiveness of mindfulness-based group therapy compared to the usual opioid dependence treatment. Iran J Psychiatry 2015;10:175-184.
47. Institute of Medicine. Complementary and Alternative Medicine in the United States. Washington, DC: National Academies Press; 2005.
48. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washing-ton, DC: National Academies Press; 2011.
49. Institute of Medicine. Psychosocial Interventions for Mental and Substance Use Disorders: A Framework for Establishing Evidence-based Standards. Washington, DC: National Academies Press; 2015.
50. Irvin JE, Bowers CA, Dunn ME, et al. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol 1999;67:563-570.
51. Lancaster T, Hajek P, Stead LF, et al. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006;166:828-835.
52. Lee K-H, Bowen S, An-Fu B. Psychosocial outcomes of mindfulness-based relapse prevention in incarcerated substance abusers in Taiwan: a preliminary study. J Subst Use 2011;16:476-483.
53. Marlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York, NY: Guilford Press; 1985.
54. McCown D, Reibel D. Mindfulness and mindfulness-based stress reduction. In: Monti DA, Beitman BD, editors. Integrative Psychiatry. New York, NY: Oxford University Press; 2010. p. 289-338. 494, xvii.
55. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-1695.
56. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
57. Morone NE, Greco CM, Weiner DK. Mindfulness meditation for the treat-ment of chronic low back pain in older adults: a randomized controlled pilot study. Pain 2008;134:310-319.
58. National Drug Intelligence Center. The Economic Impact of Illicit Drug Use on American Society. Washington, DC: US Department of Justice; 2011.
59. National Institute on Drug Abuse. Addiction science: from molecules to managed care. Bethesda, MD: National Institute on Drug Abuse; 2008.
60. Oikonomou MT, Arvanitis M, Sokolove RL. Mindfulness training for smoking cessation: a meta-analysis of randomized-controlled trials. J Health Psychol 2016. doi:10.1177/135910531663766.
61. Ramel W, Goldin PR, Carmona PE, et al. The effects of mindfulness meditation on cognitive processes and affect in patients with past depression. Cognit Ther Res 2004;28:433-455.
62. Ramo DE, Brown SA. Classes of substance abuse relapse situations: a comparison of adolescents and adults. Psychol Addict Behav 2008;22:372.
63. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health 2011;34:135-143.
64. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. The Lancet 2009;373:2223-2233.
65. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007;27:2349-2356.
66. Segal Z, Williams J, Teasdale J, et al. The mindful way through depression. New York: The Guilford Press; 2007.
67. Sidik K, Jonkman JN. Robust variance estimation for random effects meta-analysis. Comput Stat Data Anal 2006;50:3681-3701.
68. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2005: Discharges From Substance Abuse Treatment Services: DASIS Series: S-41. Dept of Health & Human Services publication No. (SMA) 08-4314, in: Services, U.D., o.H.H., (Ed.). Rockville, MD; 2008.
69. Teasdale JD, Segal ZV, Williams JMG, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68:615.
70. Uhlig DJ. Mindfulness based relapse prevention and the matrix model in substance abuse relapse prevention. Dissertation Abstracts Int B Sci Eng 2009;70:2596.
71. Viechtbauer W, Viechtbauer MW. Package 'metafor'; 2015. Available at: http://cran.r-project.org/web/packages/metafor/metafor.pdf. Accessed August 7, 2016.
72. Viechtbauer W, López-López JA, Sánchez-Meca J, et al. A comparison of procedures to test for moderators in mixed-effects meta-regression models. Psychol Methods 2015;20:360-374.
73. Walsh R, Shapiro SL. The meeting of meditative disciplines and Western psychology: a mutually enriching dialogue. Am Psychol 2006;61:227.
74. Way BM, Creswell JD, Eisenberger NI, et al. Dispositional mindfulness and depressive symptomatology: correlations with limbic and self-referential neural activity during rest. Emotion 2010;10:12.
75. Witkiewitz K, Bowen S. Depression, craving, and substance use following a randomized trial of mindfulness-based relapse prevention. J Consult Clin Psychol 2010;78:362-374.
76. Witkiewitz K, Marlatt GA. Relapse prevention for alcohol and drug problems: that was Zen, this is Tao. Am Psychol 2004;59:224-235.
77. Witkiewitz K, Lustyk MK, Bowen S. Retraining the addicted brain: a review of hypothesized neurobiological mechanisms of mindfulness-based re-lapse prevention. Psychol Addict Behav 2013;27:351-365.
78. Witkiewitz K, Bowen S, Harrop EN, et al. Mindfulness-based treatment to prevent addictive behavior relapse: theoretical models and hypothesized mechanisms of change. Subst Use Misuse 2014;49:513-524.
79. Witkiewitz K, Warner K, Sully B, et al. Randomized trial comparing mindfulness-based relapse prevention with relapse prevention for women offenders at a residential addiction treatment center. Subst Use Misuse 2014;49:536-546.
80. World Health Organization. Global Status Report on Alcohol and Health. Geneva, Switzerland: World Health Organization; 2014.
81. Xue S, Tang Y-Y, Posner MI. Short-term meditation increases network efficiency of the anterior cingulate cortex. Neuroreport 2011;22: 570-574.
82. Zgierska A. Mindfulness Meditation for Health. ClinicalTrials.gov Identifier: NCT01056484; 2014.
83. Zgierska A, Rabago D, Zuelsdorff M, et al. Mindfulness meditation for alcohol relapse prevention: a feasibility pilot study. J Addict Med 2008;2: 165-173.
84. Zgierska A, Rabago D, Chawla N, et al. Mindfulness meditation for substance use disorders: a systematic review. Subst Abuse 2009;30:266-294.